“…report more contemporary outcomes after ViV TAVR in low- to intermediate-risk patients. 10 In a prospective, single-arm, multicenter study, the investigators studied 97 patients (out of 165 patients screened) who underwent ViV TAVR using Sapien 3 valves between 2017 and 2019. In this younger, lower-risk cohort (mean age 67 years, Society of Thoracic Surgeons (STS) Predicted Risk of Mortality 2.9%), there were no deaths at 1 year, and stroke occurred in 2 patients.…”